ソラスキー医療センター軟部組織・骨腫瘍科部長 – メリムスキー教授は、複雑な肝臓がんの症例を専門としています。
ナグラー教授は、シェバ医療センターで低強度同種移植の先駆者であり、血液学における世界的に認められたリーダーです。
3,500件以上のロボット手術実績 – トヴァルジェク医師は、ダヴィンチ・ロボットのメーカーであるIntuitive Surgical社から認定を受けた第一人者です。
メフメット・カラジャ教授（医学博士）は、メディカル・パーク・アンタルヤ病院コンプレックスにて婦人科がんおよび腹腔鏡下手術を専門としています。
フォーブス誌によりイスラエル最高の医師の一人に選ばれたナフマニ教授は、シェバ医療センターの一般外科部門を率いています。
アルモグ・ベン＝ヤーコフ医師は、シェバ医療センターにてHIPEC（腹腔内温熱化学療法）を併用した腫瘍減量手術を行っており、2018年以降200件以上のHIPEC手術実績があります。
ムスタファ・ソラック医師は900件以上の手術を執刀し、世界トップクラスの腫瘍学病院であるMDアンダーソンがんセンターで研修を受けました。
ラナ・ビジェリッチ医師は、Centro Médico Teknonにて腹膜播種および肝臓がん手術を専門としています。米国でポール・シュガーベイカー教授の下で研修を受けました。
准教授のタフシン・オザトゥル医師は、Valued Med Hub病院にて1,100件以上の治療実績を持ち、複雑な腫瘍症例を専門としています。
ロン・グリーンバーグ医師は肝臓がん切除を専門とし、_doctor_234_年以上の経験を持ち、開腹手術と低侵襲手術の両方を行っています。
テルアビブ医療センターの腫瘍内科入院部門ディレクター。ステファンスキー医師は、イスラエル屈指の病院で肝臓がん専門チームを率いています。
イスラエル屈指のウィップル手術専門医であるクラウズナー博士は、ソウラスキー医療センターの外科部長を務めています。
准教授のユスフ・アチクギョズ博士は、アンカラのロクマン・ヘキム大学病院で肝臓がん治療を専門としており、オハイオ州立大学での国際的な研修経験があります。
32 年 肝臓がん手術を専門とする – ベン・ハイム医師は、ソウラスキー医療センターにおけるイスラエル屈指の消化器腫瘍学の専門家です。
BKZ Solingenにて化学療法、免疫療法、分子診断を統合し、肝臓がん治療を専門とする主任医師。
オザトリ准教授は、Istinye Liv大学病院にて消化器がんの治療を専門とし、個別の治療計画を提供しています。
ヤーコフ・ローレンス医師は、シェバ医療センターの放射線腫瘍科部長です。精密放射線治療と神経腫瘍学を専門としています。ローレンス医師は、膵臓がんの疼痛管理のための腹腔神経叢ラジオサージェリー（放射線外科）の先駆者です。専門分野における最高の名誉の一つであるFASTROの称号を保持しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 41年の経験 | 複雑な肝臓がんの症例 | トップクラスの医療センターで肝臓がんおよび骨がん専門ユニットを率いる。フェローシップや主要な腫瘍学会への所属により国際的に認められている。 | イスラエル | から $950 | |
| #2 | 46年の経験 | 複雑な血液がん | 低強度移植プロトコルの先駆者であり、イスラエルの臍帯血バンクを創設。元EBMT委員会委員長であり、スタンフォード大学でのフェローシップ経験を持つ。 | イスラエル | お問い合わせください | |
| #3 | 36年の経験 | ロボット支援による肝臓がん切除 | ダヴィンチ・ロボット手術においてIntuitive Surgical社から認定を受けた第一人者。ロボット手術専門センターを率い、複雑な症例において豊富な経験を持つ。 | チェコ共和国 | お問い合わせください | |
| #4 | 31年の経験 | 婦人科がん | 保健省の研修を受けた婦人科腫瘍学の専門家。腹腔鏡下手術とハイリスク妊娠の専門知識を持つ元臨床部長。 | トルコ | お問い合わせください | |
| #5 | 28年の経験 | 複雑な肝臓がんの症例 | 高度な低侵襲技術を駆使する肝胆膵外科の第一人者。フォーブス誌によりイスラエル最高の医師の一人と評価されている。 | イスラエル | お問い合わせください | |
| #6 | 20年の経験 | 消化器がん | 腫瘍学の世界的リーダーであるMDアンダーソンがんセンターで研修。900件以上の手術実績があり、複雑な消化器がんの症例に精通している。 | トルコ | から $100 | |
| #7 | 28年の経験 | 複雑な肝臓がん症例 | 腹膜播種および肝臓がん手術を専門とする。米国外科専門医委員会認定医であり、外科的卓越性に対する多数の受賞歴を持つ。Inova Fairfax病院の元研究ディレクター。 | スペイン | お問い合わせください | |
| #8 | 23年の経験 | 肝臓がん手術 | 消化器がんおよび肝臓がんを専門とし、1,100件以上の治療実績を持つ。トップクラスの腫瘍学研究病院で研修を受けた准教授。 | トルコ | お問い合わせください | |
| #9 | 35年の経験 | 複雑な肝臓がんの症例 | ウィップル手術を含む、肝臓がんの開腹手術および低侵襲手術を専門とする。主要な医療センターで結腸直腸外科部長を務める。 | イスラエル | お問い合わせください | |
| #10 | 26年の経験 | 複雑な肝臓がんの症例 | イスラエルの主要病院で腫瘍内科入院部門を統括。臨床経験と最先端の研究参加を融合させています。内科と腫瘍学の両方の専門トレーニングを受けています。 | イスラエル | から $750 |